Sustained exogenous expression of therapeutic levels of IFN-gamma ameliorates atopic dermatitis in NC/Nga mice via Th1 polarization

The Journal of Immunology : Official Journal of the American Association of Immunologists
Kayoko HattoriYoshinobu Takakura

Abstract

The short in vivo half-life of IFN-gamma can prevent the cytokine from inducing immunological changes that are favorable for the treatment of Th2-dominant diseases, such as atopic dermatitis. To examine whether a sustained supply of IFN-gamma is effective in regulating the balance of Th lymphocyte subpopulations, plasmid vector encoding mouse IFN-gamma, pCpG-Mugamma, or pCMV-Mugamma was injected into the tail vein of NC/Nga mice, a model for human atopic dermatitis. A single hydrodynamic injection of a CpG motif reduced pCpG-Mugamma at a dose of 0.14 microg/mouse resulted in a sustained concentration of IFN-gamma in the serum, and the concentration was maintained at >300 pg/ml over 80 d. The pCpG-Mugamma-mediated IFN-gamma gene transfer was associated with an increase in the serum concentration of IL-12, reduced production of IgE, and inhibition of mRNA expression of IL-4, -5, -10, -13, and -17 and thymus and activation-regulated chemokine in the spleen. These immunological changes were not clearly observed in mice receiving two injections of 20 microg pCMV-Mugamma, a CpG-replete plasmid DNA, because of the transient nature of the expression from the vector. The mice receiving pCpG-Mugamma showed a significant reduction in the ...Continue Reading

References

Mar 14, 1995·European Journal of Pharmacology·Y KuraishiM Satoh
Jun 1, 1994·Journal of Dermatological Science·M Furue
Feb 1, 1993·The Journal of Experimental Medicine·P ChomaratP Miossec
Jan 23, 1998·The Journal of Allergy and Clinical Immunology·J PunnonenJ E de Vries
Feb 12, 1998·The New England Journal of Medicine·A D Luster
Oct 3, 1998·Experimental Dermatology·J D BosJ H Sillevis Smitt
Jan 14, 1999·Journal of Leukocyte Biology·C H Kim, H E Broxmeyer
Apr 20, 1999·The Journal of Clinical Investigation·J M SpergelR S Geha
Jul 22, 1999·Clinical Immunology : the Official Journal of the Clinical Immunology Society·C N EllisK D Cooper
Oct 19, 1999·The Journal of Clinical Investigation·C VestergaardK Matsushima
Aug 21, 2001·Clinical Pharmacokinetics·J M HarrisM Modi
Jan 10, 2002·Journal of Pharmaceutical Sciences·Husam M Younes, Brian G Amsden
May 25, 2002·Molecular Therapy : the Journal of the American Society of Gene Therapy·Nelson S YewSeng H Cheng
Dec 25, 2002·Molecular Therapy : the Journal of the American Society of Gene Therapy·Naoki KobayashiYoshinobu Takakura
Nov 20, 2004·Clinical and Experimental Dermatology·A Grassegger, R Höpfl
Feb 1, 2005·Journal of Controlled Release : Official Journal of the Controlled Release Society·Frank GuBrian G Amsden
Feb 22, 2005·International Archives of Allergy and Immunology·Choon-Sik ParkIl Yup Chung
Oct 18, 2005·Acta Pharmacologica Sinica·Jian QiuYu-hong Xu
Nov 1, 2005·Journal of Controlled Release : Official Journal of the Controlled Release Society·Makiya NishikawaMitsuru Hashida
Jul 25, 2006·Journal of Controlled Release : Official Journal of the Controlled Release Society·Fa-ming ChenYan Jin
Oct 7, 2006·Free Radical Biology & Medicine·Kenji HyoudouMitsuru Hashida
Mar 21, 2007·International Journal of Cancer. Journal International Du Cancer·Hiroki KawanoYoshinobu Takakura
Apr 10, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Takeshi SudaDexi Liu

❮ Previous
Next ❯

Citations

Nov 8, 2012·Evidence-based Complementary and Alternative Medicine : ECAM·Min Ju Kim, Se-Young Choung
Dec 16, 2011·World Journal of Gastroenterology : WJG·Hussein M Atta
Nov 28, 2013·Human Gene Therapy. Clinical Development·Yuki TakahashiYoshinobu Takakura
Jul 9, 2013·Bioscience, Biotechnology, and Biochemistry·Shiro TakedaMasahiko Kurokawa
Aug 23, 2011·Immunopharmacology and Immunotoxicology·Yun Hwan Kang, Heung Mook Shin
Sep 22, 2012·Journal of Drug Targeting·Kanitta WatcharanurakYoshinobu Takakura
Jul 17, 2015·The British Journal of Nutrition·Eva M M VelezGabriela Perdigón
Dec 17, 2014·Molecular Therapy : the Journal of the American Society of Gene Therapy·Yeqin WangTakeshi Shimosato
Dec 15, 2015·EURASIP Journal on Bioinformatics & Systems Biology·Piyali GanguliRam Rup Sarkar
Jul 2, 2014·American Journal of Rhinology & Allergy·Ching-Feng HuangHo-Jen Peng
Oct 2, 2012·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Yuki Takahashi
Nov 5, 2010·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Makiya NishikawaYoshinobu Takakura
Dec 5, 2012·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Mitsuru AndoYoshinobu Takakura
Nov 22, 2011·Clinical and Experimental Medicine·Yunes PanahiEhsan Abolhasani
Apr 26, 2012·Experimental Animals·Akane TanakaHiroshi Matsuda
Mar 6, 2018·Immune Network·Hyun Jung ParkSeokmann Hong
Apr 4, 2013·Chemical Society Reviews·Mahmoud Elsabahy, Karen L Wooley
Dec 21, 2017·Inflammation and Regeneration·Pawinee RerknimitrKenji Kabashima
Oct 16, 2015·BMC Complementary and Alternative Medicine·Hyun-Joong YoonBong-Whan Ahn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.